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Abstract
Background: Retention on lifelong antiretroviral therapy (ART) is essential in sustaining treatment success while
preventing HIV drug resistance (HIVDR), especially in resource-limited settings (RLS). In an era of rising numbers of
patients on ART, mastering patients in care is becoming more strategic for programmatic interventions. Due to
lapses and uncertainty with the current WHO sampling approach in Cameroon, we thus aimed to ascertain the
national performance of, and determinants in, retention on ART at 12 months.
Methods: Using a systematic random sampling, a survey was conducted in the ten regions (56 sites) of Cameroon,
within the “reporting period” of October 2013–November 2014, enrolling 5005 eligible adults and children. Performance
in retention on ART at 12 months was interpreted following the definition of HIVDR early warning indicator: excellent
(>85%), fair (85–75%), poor (<75); and factors with p-value < 0.01 were considered statistically significant.
Results: Majority (74.4%) of patients were in urban settings, and 50.9% were managed in reference treatment centres.
Nationwide, retention on ART at 12 months was 60.4% (2023/3349); only six sites and one region achieved acceptable
performances. Retention performance varied in reference treatment centres (54.2%) vs. management units (66.8%),
p < 0.0001; male (57.1%) vs. women (62.0%), p = 0.007; and with WHO clinical stage I (63.3%) vs. other stages (55.6%),
p = 0.007; but neither for age (adults [60.3%] vs. children [58.8%], p = 0.730) nor for immune status (CD4351–500 [65.9%]
vs. other CD4-staging [59.86%], p = 0.077).
Conclusions: Poor retention in care, within 12 months of ART initiation, urges active search for lost-to-follow-up
targeting preferentially male and symptomatic patients, especially within reference ART clinics. Such sampling strategy
could be further strengthened for informed ART monitoring and HIVDR prevention perspectives.
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Background
With a total of 145,038 adults and children receiving anti-
retroviral therapy (ART) out of 623,350 people living with
HIV (PLHIV) in Cameroon, scalability of ART is a burning
priority to the national AIDS programme [1, 2]. Of note,
Cameroon recently adopted the 2013 World Health
Organization (WHO) public health recommendations of
the consolidated guidelines on the use of antiretroviral
drugs for treating and preventing HIV infection, increasing
eligibility of ART based on CD4 count (from the former
threshold of ≤350 to ≤500 cells/mm3) and providing uni-
versal access to lifelong ART for HIV-infected children
under five years and for HIV-infected pregnant women in
the context of the prevention of mother-to-child transmis-
sion (PMTCT) of HIV (transitioning from Option-A to
Option-B+) [3, 4]. These implications would lead to ~80%
enrolment on ART among people diagnosed HIV positive,
thus suggesting the need of innovative strategies for effect-
ive and successful programmatic ART uptakes [3, 5].
Ensuring a successful ART programme in this new
therapeutic era requires evidence-based findings on pro-
grammatic, clinic and patient factors associated with na-
tional performance [5, 6]. Our experience in assessing
these factors locally, using early warning indicators
(EWI) of HIV drug resistance (HIVDR), consistently re-
veals pharmacy stock-outs and delayed pill pick-up as
major factors favoring HIVDR emergence; while prescrib-
ing/dispensing practices remain appropriate, indicators of
retention in care and lost to follow-up are fluctuating,
making it challenging to design and implement reasonable
public health interventions nationwide [7–9], especially
with the changing paradigms in ART [5].
Retaining patients on lifelong ART, is an essential
component in HIVDR prevention through adherence
promotion, considerably improved the clinical and im-
munological outcomes [10, 11], reduced lost to follow-
up and prolong the life expectancy of treated-patients
[3]. As this indicator remains with uncertainty [7–9], it
became crucial for the national AIDS programme to de-
lineate the country performance in patient retention on
ART as well as related determinants. Such investigation
would provide a reliable representativeness of Camer-
oon’s capacity in retaining patients on ART and prompt
real time corrective measures while transitioning to
current treatment strategies [3, 4].
In a context of declining trends in HIVDR EWI, the
number of HIV clinics with satisfactory performance in
patient retention on ART dropped drastically (from 70
to 0%) in selected sites of our national ART programme
[8]. Moreover, retention on ART varied significantly be-
tween urban and rural settings in Cameroon [9], thereby
stressing the necessity of in-depth understanding of dis-
parities surrounding this key indicator of patient adher-
ence to ART program [5, 6].
In terms of programmatic perspectives, an accurate
mastering of patients in care provide a better accountabil-
ity and planning for ARV drug procurement, thereby re-
ducing events of discontinuous drug supply as previously
reported [7–9]. Of note, drug shortage suggests ART
interruption, which is a direct indicator of suboptimal
ARV adherence and higher risks of HIVDR emergence in
a context where low-genetic barrier drugs (i.e. lamivudine
[3TC], emtricitabine [FTC], nevirapine [NVP], efavirenz
[EFV]) are widely used for patient management [3, 4].
Therefore, poor retention on ART automatically results in
higher lost to follow-up and HIVDR emergence and sub-
sequent transmission to newly infected people within the
communities [4, 5].
To minimize lost to follow-up and its associated risks of
HIVDR, the WHO recommends to evaluate “retention in
care at 12 months of ART” as part of five simplified EWIs
(on- time pill pick-up; retention in care at 12 months;
pharmacy stock-outs; dispensing practices; and virological
suppression) [4, 5, 9]. Following the WHO sampling strat-
egy, we earlier evaluated EWIs on selected ART clinics
based on predefined criteria [4–9]. Following the WHO
methodology during previous assessments, we found it
difficult to identify specific programmatic factors associ-
ated with performance of retention in care at 12 months
of ART at clinic-, at regional-, or at national-levels [7–9].
We aimed to ascertain the national ART programme
performance on retention in care at 12 months of ART
and associated factors in Cameroon, for the implementa-
tion of an optimal strategy against preventable HIVDR
and for a mastering of ARV needs in an era of national
treatment uptakes.
Methods
Study design and target populations
A cohort-study was conducted from February 23 to 06
March 06, 2015 in all the ten regions of Cameroon, among
PLHIV initiating ART in the “enrolment period” ranging
from October 2013 to December 2013 and followed-up
for 12 months (i.e. October 2014 to December 2014).
Thus, study “reporting period” ranges from October 2013
to November 2014.
Sampling method
Following a systematic random sampling with unequal
probability at two-levels, all ten regions were systematic-
ally included in the survey, followed by a random selection
of reference treatment centres and HIV management
units in each region. Main exclusion criteria were sites
with non-significant number of patients (<30) initiating
ART within the defined “enrolment period”, calculated
using the following formula:
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n ¼ t
2  p 1 − pð Þ
m2
With n = required minimum sample size; t = Z value at
a confidence interval of 95% (1.96); p = assumed rate of
retention at 12 months of ART; and m = error rate
marge at 1% (0.01).
Overall, 56 sites were enrolled and their characteristics
described: regional location, geographic settings (urban
versus rural), and level of HIV clinic (reference treat-
ment centre versus HIV management unit). In each se-
lected site, patients initiating ART during the “enrolment
period” were consecutively included until complete sam-
pling for the study (for a total of 5005 in number).
Data collection
Data were abstracted from ART registers, medical files
and pharmacy registers used to monitor patients at the
respective ART clinic, and entered into EWI 2 abstrac-
tion tool as previously described [9]. Incoherent data
were resolved by retrieving additional record documents
available at the clinic.
Quality assurance and data validation
To ensure reliability in collected data, only staff (statisti-
cian and experienced personnel) trained on HIV data
management participated in the data abstraction process.
Supervisors were Public Health experts from the central
level with field experience on the collection and report-
ing of data in the ART programme. After on-site valid-
ation (mainly for data readability and completeness) on
5005 patient files, abstracted data were centralised at the
national level, whereby a second validation (mainly for
verifying data consistency) was conducted through a
double electronic data-entry; leading to 66.91% inclusion
in the final dataset (Fig. 1).
Data analysis
Interpretation of data was performed according to the
definition of EWI 2 as described in Table 1. Chi
Square test was used in assessing statistical associa-
tions, with p-value <0.01 considered significant.
Availability of data and materials
The data supporting the findings are provided in the
main paper and in additional supporting files uploaded
as supplement contents with this manuscript.
Results
Socio-demographic characteristics of the study
population
Of all 3349 PLHIV in the validated dataset from the
56 study sites, distribution according to geographic
settings showed that 2491 (74.4%) and 858 (25.6%)
were respectively in the urban and rural settings. Ac-
cording to level of HIV clinic, 50.9% were enrolled in
a reference treatment centre; while for regional distri-
bution, the Centre, Northwest, Littoral, and Southwest
regions were highly represented (17.2, 14.8, 13.8, and
12.3% respectively), as shown in supplemental digital
content (Additional file 1: SDC 1).
Out of 3256 PLHIV initiating ART whose gender and
age were recorded in the 56 study sites, 2201 (67.6%)
were female (gender ratio: two women for one man,
p < 0.0001); mean age was 36.1 years (+/− 12.2), min-
max: 0.16 – 74; and only 4.2% were children or adoles-
cents aged <15 years (Additional file 1: SDC 2).
Clinical characteristics of the study population
Of the 2163 patients with available clinical classification
at ART initiation, 1279 (59.1%) were at the WHO clin-
ical stage III, with 60.0 and 58.7% respectively in the
male and female populations.
Fig. 1 Data collection and validation procedure
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Of the 2621 patients with available CD4 recorded at
ART initiation, a median of 223 CD4 cells/mm3 [IQR:
52; 384] was recorded, and the majority (86.5%) had ≤
350 CD4 cells/mm3, while <5% had a CD4 count
>500 cells/mm3.
All 3349 patients had their initial ART regimens re-
corded, and predominant regimens were tenofovir
(TDF)/3TC/EFV (44%) and zidovudine (AZT)/3TC/NVP
(31.6%), as detailed in Table 2.
Performance in retention on ART
Retention according to geographic settings
Globally, the national level of retention in care
12 months after ART initiation was 60.4% (2023/3349),
indicating an overall poor performance in patient reten-
tion shortly after ART initiation, with a significantly
lower performance in urban (58.5%) compared to rural
(66.0%) settings, p < 0,0001.
According to regions, retention capacity varied consid-
erably, with the highest performance reported in the
Littoral Region (75.1%), followed by the East, Centre and
Adamawa regions (70.2, 64.8, and 63.4% respectively).
Thus, no region in the country had an excellent/desir-
able performance, and only one region (Littoral) had a
fair performance, while the West and Far-North regions
that registered the poorest performances (42.8 and
47.4% respectively), as shown in Table 3.
Retention according to HIV clinic levels
According to clinic levels, reference treatment cen-
tres had an overall performance of 54.2% against
66.8% in HIV management units, indicating paradox-
ically a better capacity of low-level clinics in retain-
ing patients on ART. Of note, the HIV management
unit with the highest performance had 93.1% (in the
East region) while the reference treatment centre
with the highest performance had 83.5% (in the
Littoral region), indicating respectively an excellent
and a fair capacity for retention on ART (Additional
file 1: SDC 3).
Table 1 Definition and data analysis of retention on ART
Title Definition Numerator Denominator Target
Retention in care at
12 months of ART
Percentage of adults and
children known to be alive
and on ART 12 months after
initiation
Number of adults and children
who are still alive and on ART
12 months after initiating
treatment
Total number of adults and children
(excluding transfers out) who initiated
ART and were expected to achieve








Legend. ART antiretroviral therapy. Were classified as lost to follow-up patients who fail to return for drug pick-up afterthree consecutive months following the last
expected pharmacy appointment date
Table 2 Distribution of participants by WHO-staging, CD4 count and initial ART regimens
Male Female Total
n % n % n %
WHO clinical staging I 80 11.5% 274 18.6% 354 16.4%
II 86 12.4% 204 13.9% 290 13.4%
III 416 60.0% 863 58.7% 1279 59.1%
IV 111 16.0% 129 8.8% 240 11.1%
Total 693 100.0% 1470 100.0% 2163 100.0%
CD4 count 0 to 350 737 89.0% 1541 85.9% 2278 86.9%
351 to 500 59 7.1% 164 9.1% 223 8.5%
>500 32 3.9% 88 4.9% 120 4.6%
Total 828 100.0% 1793 100.0% 2621 100.0%
Initial ART regiments AZT/3TC/EFV 142 13.1% 292 12.9% 434 13.0%
AZT/3TC/NVP 347 32.0% 710 31.3% 1057 31.6%
TDF/3TC/EFV 489 45.2% 986 43.5% 1475 44.0%
TDF/3TC/NVP 60 5.5% 192 8.5% 252 7.5%
Others 45 4.2% 86 3.8% 131/ 3.9%
Total 1083 100.0% 2266 100.0% 3349 100.0%
Legend. ART antiretroviral therapy, WHO World Health Organisation, 3TC lamivudine, AZT zidovudine, EFV Efavirenz, NVP nevirapine, TDF Tenofovir
In bold are the most prevalent data in WHO clinical stage, CD4 count, and initial ART in the study population
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Factors associated with levels of retention on ART after
12 months
Association between demographic profile and retention
on ART
The overall gender distribution at 12 months after ART
initiation revealed that 62.0% (1405) women compared
to 57.1% (618) men were still in care, indicating a
significantly better adherence of women to the national
ART program, p = 0.007. Similar trends were observed
when comparing retention in care between women
(68.3%) and men (63.6%) followed-up in HIV manage-
ment units (p = 0.057), as well as in reference treatment
centres (55.8% versus 50.9% respectively), p = 0.018.
According to age groups, paediatrics (children and
adolescents < 15 years) had similar retention rates
compared to older patients (58.8 and 60.3%, respectively,
p = 0.730); with a slightly lower performance observed
among children aged 5–9 years (47.2% versus 63% for
other children age, p = 0.099), as shown in Table 4.
Association between clinical characteristics and retention
on ART
Clinical analysis revealed that 12 months retention on
ART seems decreasing from WHO clinical stage I to IV,
with the highest performance (63.3%) reported among pa-
tients with at WHO clinical stage I while the poorest
(55.4%) was among ones at WHO clinical stage IV, p =
0.007. With a median of 223 CD4 cells/mm3, we observed
a slightly higher retention on ART at 12 months for pa-
tients who started treatment with 351–500 cells/mm3
(65.9%) compared to other categories (59.86% for ones
with = <350 CD4 cells/mm3 and with >500 CD4 cells/
mm3, p = 0.077). Overall, clinical parameters showed low
rates of retention (below performance limit of 75%), thus
indicating higher risk of HIVDR emergence (Table 5).
Table 3 Retention on ART by geographic settings and by region
Regions Urban Rural Total
n/N % n/N % n/N %
Adamawa 130/205 63.4% NAa NAa 130/205 63.4%
Centre 109/162 67.3% 265/415 63.8% 374/577 64.8%
East 91/155 58.7% 88/100 88.0% 179/255 70.2%
Far-North 66/163 40.5% 26/31 83.9% 92/194 47.4%
Littoral 346/461 75.1% NAa NAa 346/461 75.1%
North 104/166 62.7% 35/69 50.7% 139/235 59.1%
Northwest 141/264 53.4% 152/233 65.2% 293/497 59.0%
West 133/311 42.8% NAa NAa 133/311 42.8%
South 105/201 52.2% NAa NAa 105/201 52.2%
Southwest 232/413 56.2% NAa NAa 232/413 56.2%
Total 1457/2501 58.3% 566/848 66.7% 2023/3349 60.4%
Legend. n: frequency; %: proportion of patients in care for each region and in
the total study population
a: NA (Not applicable), due to selection of no rural site following the
random sampling
In bold are the most prevalent data on retention from the national regions
Table 4 Retention on ART 27 by gender, age and level of HIV clinics
Reference treatment centre HIV management unit Total
n/N % n/N % n/N %
Gender Male 284/558 50.9% 334/525 63.6% 618/1081 57.2%
Female 641/1148 55.8% 764/1118 68.3% 1405/2266 62.0%
Age range Less than 4 years 13/25 52.0% 28/40 70.0% 41/65 63.1%
5–9 years 8/19 42.1% 9/17 52.9% 17/36 47.2%
10–14 years 7/17 41.2% 15/18 83.3% 22/35 62.9%
15–19 years 12/20 60.0% 15/30 50.0% 27/50 54.0%
20–24 years 66/127 52.0% 74/108 68.5% 140/235 59.6%
25–29 years 134/260 51.5% 168/233 72.1% 302/493 61.3%
30–34 years 169/312 54.2% 182/294 61.9% 351/606 57.9%
35–39 years 134/240 55.8% 187/280 66.8% 321/520 61.7%
40–44 years 126/234 53.8% 158/230 68.7% 284/464 61.2%
45–49 years 84/157 53.5% 97/149 65.1% 181/306 59.2%
50–54 years 71/119 59.7% 64/102 62.7% 135/221 61.1%
55 years and 53/107 49.5% 88/118 74.6% 141/225 62.7%
Age range Children 28/61 45.9% 52/75 69.3% 69.3% 58.8%
Adults 849/1575 53.9% 1033/1544 66.9% 1882/3119 60.3%
Total Total 925/1706 54.2% 1098/1643 66.8% 2023/3349 60.4%
Legend. n: frequency; %: proportion of patients in care for each region and in the total study population; Reference treatment centre provides mentorship to HIV
management units within his health area. In bold are the most prevalent data on retention on ART according to gender and to age range
Billong et al. BMC Infectious Diseases  (2016) 16:678 Page 5 of 9
However, retention performance at all clinical parameters
was significantly greater in HIV management units com-
pared to reference treatment centres (66.8% versus 54.2%,
respectively); p < 0.0001.
Classification levels of retention on ART by health
facilities
Overall, only six out of 56 (10.71%) health facilities had
acceptable performance for retention on ART at
12 months, among which 5.36% (3/56) with excellent
(>85%) performance (Ngaoundéré Presbyterian Hospital
[93.1%], CBC of Mboppi [89.5%], PR Garoua Boulai
[88%]), and 5.36% (3/56) with fair (75–85%) performance
(HD Pette [83.9%], Douala Laquintinie Hospital [83.5%],
and DH Mamfe [81.3%]), which were mostly HIV man-
agement units from diverse regions in Cameroon. Poor-
est performances were observed from an HIV
management unit (NKAMBE DH [6.2%]) and a refer-
ence treatment centre (Yaoundé General Hospital
[18.9%]). Thus, 89.29% of health facilities had a poor
(<75%) performance in retention on ART at 12 months;
indicating an overall high risk of HIVDR emergence in
these ART clinics.
Discussion
As an indicator of potential loss to follow-up in ART
programs and a tool for estimates in ARV procure-
ment and supply, patient retention in care also serves
in tailoring adherence support towards a better con-
trol of preventable HIVDR [5, 6]. As compared to
previous studies in Cameroon [7–9], our findings pro-
vide a prime estimate of the country capacity both in
enrolling and in retaining patients on care 12 months
after ART initiation. Importantly, the random sam-
pling, across 56 ART clinics from all 10 regions of
Cameroon, is innovative as it generates more mean-
ingful evidence-based interventions, compared to the
WHO primary sampling strategy [5, 6].
From this random sampling, only 60% of patients were
still in care at 12 months after ART initiation, resulting
in a poor national performance (i.e. <75%) for patient re-
tention on ART, translated into 40% potential lost to
follow-up [12]. As loss to follow-up are known as pos-
sible HIVDR, national ART programs in SA has ~40%
likelihood of experiencing HIVDR emergence in a short-
medium run [10, 11]. Of note, only 10.71% ART clinics
and only one region (Littoral) had acceptable perfor-
mances (excellent or fair), suggesting that ~90% of ART
clinics as well as 90% of regions are experiencing high
risks of HIVDR due to poor retention on ART, similar to
findings from other SSA-settings [13]. The high per-
formance observed in a reference centre of the Littoral
is likely due to ongoing project that provides additional
support for patient monitoring onsite, thus fostering ad-
herence to care, as earlier addressed [9]. Compared to
recently conducted EWI survey, performance was lower
(10.71% versus 76.92%), and worse in urban settings [9];
a disparity likely attributed to the random sampling that
gives broaden and in-depth appraisals of program func-
tioning at all levels. Retention was also significantly
lower (p < 0.0001) in HIV reference treatment centres
than in management units. This outcome could be partly
attributed to the burnout syndrome (heavy workload)
which appears higher in reference treatment centres as
we earlier reported within this national context (74.4%
patients versus 25.6% in management units), calculated
per site based on the number of trained physicians,
nurses, pharmacists/clerks, biologists/laboratory techni-
cians, counsellors, data managers, community relay
agents involved on the routine management of PLHIV
[8]. Advanced implementation of task shifting and de-
centralisation might help alleviating the burnout syn-
drome [8, 13–15]. Retention at 12 months of ART was
also problematic in African countries and beyond, sup-
porting the needs to explore other local factors (geo-
graphical landscape around a single ART clinic,
availability of transportation facilities, effectiveness of
Table 5 Retention on ART according to clinical parameters
Reference treatment centres HIV management units Total
n/N % n/N % n/N %
WHO clinical stage I 100/183 54.6% 124/171 72.5% 224/354 63.3%
II 71/158 44.9% 94/132 71.2% 165/290 56.9%
III 299/545 54.9% 493/734 67.2% 792/1279 61.9%
IV 33/99 33.3% 100/141 70.9% 133/240 55.4%
CD4 count 0–350 576/1114 51.7% 787/1164 67.6% 1363/2279 59.8%
351–500 55/93 59.1% 92/130 70.8% 147/223 65.9%
Above 500 19/35 54.3% 54/85 63.5% 73/120 60.8%
Total 925/1706 54.2% 1098/1643 66.8% 2023/3349 60.4%
Legend. n: frequency; %: proportion of patients in care for each region and in the total study population; Reference treatment centre provides mentorship to HIV
management units within his health area. In bold are the most prevalent data on retention according to WHO clinical stage and CD4 count
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decentralisation, etc.) that may be warrant public health
actions [12–19].
Our study delineates additional reasons underscoring
this poor national retention on ART. Of note, poor re-
tention was more concerning in men (p = 0.007), thus
requiring intensified adherence support to men on ART
following their daily realities and challenges [18]. As pre-
viously reported, African women are generally known to
be more adherent to ART programs [20, 21]; this might
also be attributed to attention offered to women through
the PMTCT program and cascade of health care for
mother and child (an information not captured in our
dataset), and the eventual non-adherence of male pa-
tients [22]. Due to the limited representativeness of chil-
dren (<15 years), retention on ART according to age
merits further investigations, with linkage to virological
suppression according to age groups [21, 23].
The significant risk (p = 0.007) of poor retention on
ART among potential symptomatic patients (i.e. 55.6%
WHO clinical stages I/II/III:) versus potential healthy/
asymptomatic patients (i.e. 59.1% WHO clinical stage I)
indicates the need to implement an active monitoring/
tracking system for patients suffering of any disease at
ART initiation, as well as social and financial barriers
[21, 23]. This underscores that early ART initiation
would promote retention on ART [21]. Moreover, me-
dian CD4 (223 cells/mm3) indicates an overall delay ini-
tiation of ART (though better than previous reports: 123
and 163 CD4 cells/mm3) [12, 24], which in turns predict
poor outcomes both in retention and in clinical benefits
[21, 25]. Despite no significance between CD4 range and
retention levels (p = 0.077), severely immune compro-
mised patients would likely default from care due to
clinical manifestations [23, 26], thus implying policies
for timely ART initiation as we transition to ≤500 CD4
cells/mm3 for initiation [3, 4, 19].
Decreasing retention was observed with periods of ART
initiation (October-December, p <0.02), suggesting further
understanding of related temporal barriers on defaulters
or lost to follow-up [24], especially in the frame of the
current “90-90-90” goals in RLS [27]. Thus, innovative ap-
proaches (community-based test-and-treat, mobile clinics,
use of SMS for recalls, adherence clubs, and point-of-care
monitoring) are highly necessary to curve the epidemic,
especially within SSA settings [27–33].
Study strengths
Including 56 ART clinics, in all the ten national regions,
gives room for greater country representativeness (com-
pared to previous studies [7–9]), further strengthened by
random sampling at regional level. Findings would directly
contribute for planning, monitoring and evaluation of na-
tional ART program, and for policy-implementation in
other RLS with similar challenges [5, 6].
Study limitations
Data rejection (~33%) weakens our expected study
strengths, thus indicating needs for continuous training
on data reporting in the continuum of ART programs
within such RLS. Rural settings were limited, suggesting
a two-level systematic sampling, followed by randomisa-
tion only within unique geographical strata (urban vs.
rural; reference centre vs. management units, etc.) [33].
Study-period (1-year) was a limited to assess retention
rates according to different ART-regimens, thus requir-
ing long-term cohort-studies while transitioning towards
new ART recommendations [4]. Predictors of delayed
ART initiation, and other aspects of adherence to ART
(on-time drug pickup, pill count, self-reported adher-
ence, and/or drug dosage) should be covered subse-
quently, for optimal policies.
Context-specific programmatic lessons
Despite the high capacity of the national AIDS program in
enrolling patients on ART, poor performance in retaining
these patients in care is a serious treat for ART effective-
ness and coverage. Interestingly, results predict a better
life expectancy for women over men, who appear less
likely than women to seek and adhere to ART [22]. On a
separate note, active search for patients out of care is
mandatory, including community engagement, to sustain
ART cohorts and routine drug procurement. Accelerating
task shifting and decentralisation would alleviate the ten-
tative heavy workload. Therefore, in routine practice,
follow-up/adherence support should mainly target male
and symptomatic patients initiating ART nationwide. Pro-
grammatic assessments may integrate quality of care indi-
cators [34], affordable monitoring assays [35–37], and
simplified/cost-effective ARV drug provision strategies
[38, 39] for the national ART performance, in a context of
increasing risks of HIVDR [40–42].
Conclusions
One year after ART initiation in Cameroonian clinical
settings, retention in care remains below acceptable
standards, suggesting risks of HIVDR emergence nation-
wide. Adherence interventions should focus primarily on
male and symptomatic patients, especially within refer-
ence ART clinics. Such systematic-random sampling
strategy should be further strengthened, in the frame of
the global perspectives for HIVDR prevention in RLS.
Additional file
Additional file 1: SDC 1. Distribution of the study population by
geographic settings, by level of HIV clinic, and by region. Geographical
setting is reported as rural or urban; level of HIV clinic is reported as
reference treatment centres or HIV management units; regions represent
all ten geographical regions of Cameroon. All data are reported for male,
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female and the overall population. SDC 2. Distribution of study
population by gender and by age. Data are represented in age range of
five years; an aggregated data for adults versus children is also provided.
All data are reported for male, female and the overall population. SDC 3.
Retention on ART by level of HIV clinic. Retention in care is provided for
reference treatment centres and for HIV management units, reported for
each region and for the overall geographical regions of Cameroon.
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